Fund profile by ISIN IE0000H445G8
VanEck New China UCITS ETF
Research VanEck New China UCITS ETF by ISIN IE0000H445G8: TER 0.60%, domicile Ireland, accumulating, and 1-year price performance -9.8%.
ISINIE0000H445G8
TER0.60%
DomicileIreland
Distribution policyAccumulating
IndexMarketGrader New China Screened
Fund size8M
Holdings100
1-year price performance-9.8%
Exchange listings and tradability
| Ticker | Exchange | Currency | Country | Avg daily turnover | Avg daily shares |
|---|---|---|---|---|---|
| CNEW.MI | ETFP | EUR | Ireland | €36K | 2,552 |
| CNEW.SW | SW | CHF | Ireland | €14K | 1,022 |
| CNIE.DE | XETRADefault at German brokers | EUR | Ireland | €11K | 806 |
| CEBG.L | LSE | GBP | Ireland | €2K | 164 |
| CNEW.L | LSE | USD | Ireland | €2K | 149 |
Avg daily turnover is the 90-day average, converted to euros so venues in different currencies can be compared; avg daily shares is the same window in units. The most traded listing is shown first. This fund trades on a German exchange. As of 2026-10-13.
Largest holdings
The 10 largest holdings make up 11.12% of the fund, which holds 100 positions in total. As of 2026-10-12.
| Holding | Symbol | Weight |
|---|---|---|
| WuXi Biologics (Cayman) Inc | 2269.HK | 1.17% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 1.15% |
| Amlogic (Shanghai) Co Ltd Class A | 688099.SS | 1.14% |
| Ningbo Menovo Pharmaceutical Co Ltd Class A | 603538.SS | 1.12% |
| CSPC Innovation Pharmaceutical Co Ltd Class A | 300765.SZ | 1.11% |
| Hansoh Pharmaceutical Group Co Ltd | 3692.HK | 1.10% |
| All Winner Technology Co Ltd Class A | 300458.SZ | 1.09% |
| Wuxi AppTec Co Ltd Class A | 603259.SS | 1.09% |
| NetEase Inc Ordinary Shares | 9999.HK | 1.07% |
| Simcere Pharmaceutical Group Ltd Ordinary Shares | 2096.HK | 1.07% |
Performance is the historical price return of the representative listing. Distributions are excluded and past performance is not a forecast.